The purpose of this study is to determine whether the bacteria normally present in the bowels
are different in people with constipation and to see what effect the treatment with the Food
and Drug Administration (FDA) - approved drug, lubiprostone, has on these bacteria.
Phase:
Phase 1
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
Arizona State University Takeda Pharmaceuticals North America, Inc.